Russell Conley CEO GI Cancer Institute

August 2019: An update from CEO Russell Conley

Dear Members,

The Annual Scientific Meeting has drawn to a close, and I am leaving Adelaide energised by the productive and insightful discussions and presentations. Thank you to everyone who attended, particularly those who presented their work.

I would like to congratulate everyone who received an AGITG Award at the ASM. In particular, I would like to congratulate Professor Val Gebski, who won the John Zalcberg OAM Award for Excellence in AGITG Research. Professor Gebski has made a remarkable contribution to the AGITG as a biostatistician since the formation of the group in 1991.

The AGITG Innovation Fund grant was awarded to Professor Peter Gibbs for the project ‘An organoid sensitivity testing driven umbrella study for patients with chemorefractory metastatic colorectal cancer’. The Innovation Fund is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations made through the GI Cancer Institute’s Gutsy Challenge.

Congratulations to Professor Peter Gibbs, who was awarded the 2019 AGITG Innovation Fund. This $200,000 grant will go towards the project ‘An organoid sensitivity testing driven umbrella study for patients with chemorefractory metastatic colorectal cancer’. This study will investigate a promising model for personalised therapy in an area of unmet need.

Finally, Dr Yu Jo Chua gave a presentation on the AGITG’s approach to international collaboration in cancer clinical trials at the Japanese Society of Medical Oncology Annual Meeting. He also presented a poster on INTEGRATE II, the first AGITG trial to open in a Japanese site. I would like to thank him for sharing his insights on our collaboration at the meeting.

Sincerely,
Russell Conley
Chief Executive Officer

Share